The global market for the next generation drug conjugates is expected to grow at a compounded annual growth rate (CAGR) of more than 20% during the forecast period.

Read More: https://www.rootsanalysis.com/reports/next-generation-drug-conjugates-market.html

The next generation drug conjugates, owing to their non-immunogenic nature, better clinical profile, structural stability, limited side effects, targeted delivery of payload, deeper cellular penetration, and permeability, have emerged as the viable targeted therapeutics for rare disease indications, including cancers. Over the last decade, the standard cost of medical care for rare disease indications has increased exponentially.